CY1117236T1 - Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 - Google Patents

Μονοκλωνικα αντισωματα εναντι γλυπικανης-3

Info

Publication number
CY1117236T1
CY1117236T1 CY20161100174T CY161100174T CY1117236T1 CY 1117236 T1 CY1117236 T1 CY 1117236T1 CY 20161100174 T CY20161100174 T CY 20161100174T CY 161100174 T CY161100174 T CY 161100174T CY 1117236 T1 CY1117236 T1 CY 1117236T1
Authority
CY
Cyprus
Prior art keywords
antibodies
glycican
methods
glypican
antibodies against
Prior art date
Application number
CY20161100174T
Other languages
Greek (el)
English (en)
Inventor
Jonathan Alexander Terrett
Li-Sheng Lu
Haichun Huang
Dapeng Yao
Chin Pan
Heidi Leblanc
Timothy Sproul
Mark Yamanaka
Original Assignee
E. R. Squibb & Sons, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E. R. Squibb & Sons, L.L.C. filed Critical E. R. Squibb & Sons, L.L.C.
Publication of CY1117236T1 publication Critical patent/CY1117236T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
CY20161100174T 2007-07-17 2016-03-01 Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 CY1117236T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95984507P 2007-07-17 2007-07-17
EP08796249.4A EP2178921B1 (en) 2007-07-17 2008-07-17 Monoclonal antibodies against glypican-3

Publications (1)

Publication Number Publication Date
CY1117236T1 true CY1117236T1 (el) 2017-04-05

Family

ID=39874207

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100174T CY1117236T1 (el) 2007-07-17 2016-03-01 Μονοκλωνικα αντισωματα εναντι γλυπικανης-3

Country Status (18)

Country Link
US (2) US8680247B2 (cg-RX-API-DMAC7.html)
EP (1) EP2178921B1 (cg-RX-API-DMAC7.html)
JP (2) JP5868593B2 (cg-RX-API-DMAC7.html)
KR (2) KR101527342B1 (cg-RX-API-DMAC7.html)
CN (1) CN101815726B (cg-RX-API-DMAC7.html)
AU (1) AU2008275985B2 (cg-RX-API-DMAC7.html)
CY (1) CY1117236T1 (cg-RX-API-DMAC7.html)
DK (1) DK2178921T3 (cg-RX-API-DMAC7.html)
ES (1) ES2562790T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160270T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028737T2 (cg-RX-API-DMAC7.html)
ME (1) ME02345B (cg-RX-API-DMAC7.html)
MX (1) MX2010000537A (cg-RX-API-DMAC7.html)
PL (1) PL2178921T3 (cg-RX-API-DMAC7.html)
PT (1) PT2178921E (cg-RX-API-DMAC7.html)
RS (1) RS54624B1 (cg-RX-API-DMAC7.html)
SI (1) SI2178921T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009012394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2009012394A1 (en) * 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
MY148637A (en) * 2007-09-28 2013-05-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CA2760246A1 (en) * 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
MX345399B (es) * 2010-12-28 2017-01-30 Chugai Pharmaceutical Co Ltd Metodo de cultivo de celulas animales.
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
BR112015019432A2 (pt) 2013-02-14 2017-08-22 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e uso
EA201690388A1 (ru) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
AU2016206798A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
KR20180008649A (ko) 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
US11370845B2 (en) * 2015-06-24 2022-06-28 Keio University Anti-glypican-1-immunizing antigen receptor
DK3333192T3 (da) * 2015-08-03 2021-05-31 Cafa Therapeutics Ltd Antistof imod glypican-3 og anvendelse deraf
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
JP2019505575A (ja) 2015-12-21 2019-02-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 部位特異的な結合のための変異型抗体
CN105717303A (zh) * 2016-01-29 2016-06-29 山东康力医疗器械科技有限公司 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN106084041A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种全人源抗GPC3的全分子IgG抗体及其应用
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
SG11201909728XA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
EP3630833A1 (en) 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
EA202092747A1 (ru) 2018-05-29 2021-03-16 Бристол-Маерс Сквибб Компани Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
FI3886914T3 (fi) 2018-11-30 2023-05-26 Bristol Myers Squibb Co Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä
KR20210102334A (ko) 2018-12-12 2021-08-19 브리스톨-마이어스 스큅 컴퍼니 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
CN120118189A (zh) * 2019-03-21 2025-06-10 新加坡科技研究局 针对磷脂酰肌醇蛋白聚糖-3的人单克隆抗体
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
KR20230007452A (ko) * 2020-05-07 2023-01-12 페인스 테라퓨틱스 인코포레이티드 항종양 관련 항원 항체 및 이의 용도
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
KR20240000479A (ko) * 2021-04-23 2024-01-02 상하이 헨리우스 바이오테크, 인크. 항gpc3 항체 및 사용 방법
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
KR20240112375A (ko) * 2021-08-19 2024-07-18 아디셋 테라퓨틱스, 인크. 막 결합된 글리피칸-3의 검출 방법
CN118994403B (zh) * 2021-10-15 2025-04-01 乐普创一生物科技（上海）有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
TW202432596A (zh) * 2022-11-01 2024-08-16 大陸商上海齊魯製藥研究中心有限公司 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
AU2024305352A1 (en) 2023-06-12 2025-12-04 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426001B2 (ja) 1993-09-16 2003-07-14 東芝機械株式会社 ステージ内蔵型雰囲気室装置
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
DK2208784T3 (da) 2001-06-22 2013-03-18 Chugai Pharmaceutical Co Ltd Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004067571A1 (fr) 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
JP4501859B2 (ja) 2003-06-27 2010-07-14 日本電気株式会社 薄膜トランジスタ、薄膜トランジスタ基板、電子機器及び多結晶半導体薄膜の製造方法
CN102702353A (zh) * 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
SI1800693T1 (sl) 2004-08-24 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Adjuvantna terapija z uporabo protitelesa proti glipikanu 3
RU2451030C2 (ru) 2004-10-26 2012-05-20 Чугаи Сейяку Кабусики Кайся Анти-глипикан 3-антитело, имеющее модифицированную сахарную цепь
US7988971B2 (en) * 2005-03-14 2011-08-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7744800B2 (en) 2006-01-06 2010-06-29 Molded Fiber Glass Companies Method and apparatus for controlling the stacking height of stackable products during compression molding off stops
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
WO2009012394A1 (en) * 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use

Also Published As

Publication number Publication date
ES2562790T3 (es) 2016-03-08
HUE028737T2 (en) 2017-01-30
HRP20160270T1 (hr) 2016-05-06
AU2008275985B2 (en) 2013-09-19
MX2010000537A (es) 2010-03-25
SI2178921T1 (sl) 2016-05-31
CN101815726A (zh) 2010-08-25
JP2014236734A (ja) 2014-12-18
PT2178921E (pt) 2016-03-23
PL2178921T3 (pl) 2016-06-30
DK2178921T3 (en) 2016-04-04
KR20100056467A (ko) 2010-05-27
ME02345B (me) 2016-08-31
JP2010533498A (ja) 2010-10-28
KR101570252B1 (ko) 2015-11-19
WO2009012394A1 (en) 2009-01-22
AU2008275985A1 (en) 2009-01-22
US9217033B2 (en) 2015-12-22
KR20150038732A (ko) 2015-04-08
EP2178921A1 (en) 2010-04-28
EP2178921B1 (en) 2016-01-06
CN101815726B (zh) 2013-04-03
RS54624B1 (sr) 2016-08-31
US20140186892A1 (en) 2014-07-03
KR101527342B1 (ko) 2015-06-09
US8680247B2 (en) 2014-03-25
JP5868593B2 (ja) 2016-02-24
US20100209432A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
TN2011000524A1 (en) Antibodies specific to cadherin -17
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
WO2007067991A3 (en) Human monoclonal antibodies to o8e
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
MX338754B (es) Anticuerpos humanos contra el factor tisular.
MX2010003581A (es) Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos.
IN2012DN00640A (cg-RX-API-DMAC7.html)
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2012054084A3 (en) Antibodies
CY1119351T1 (el) Αντισωματα σε adp-ριβοζυλ κυκλαση 2